[Image courtesy of Azzur]
The continued growth of the cell and gene therapy (CGT) market will increase demand for alternative cleanroom arrangements, predicts Ravi Samavedam, chief innovation officer at Azzur Group (Hatboro, Pennsylvania). “Keeping up with market forces will require an increase in demand for therapies that will outstrip current means of production,” Samavedam said. “Building facilities requires validation that can delay the manufacturing process while CDMOs are already operating at capacity. Neither alternative will satisfy growing demand.”As a case in point, Charles River expanded its cell therapy CDMO facility in Memphis, Tennessee, earlier this month. Suited for clinical and commercial cell therapy manufacturing applications, the new space has nine new processing suites, adding to an existing 16 cleanrooms.
Growing demand for CGT could drive similar growth across the sector. Worth $7…